US Exchange Filings

Apimeds Sets Stock Payment and Valuation Terms for FreeT Apitox Rights

Apimeds will issue FreeT 350,000 shares for Apitox-related rights, with the final price still to be determined. An independent valuation could trigger additional payment in cash, stock, or both—leaving investors to weigh potential dilution and an uncertain deal cost.

Apimeds Pharmaceuticals US has clarified the consideration it will pay FreeT Inc. for certain Apitox-related rights transferred to Apimeds in August. The agreement provides for an initial stock payment and could require additional compensation after an independent valuation of the rights.

The amendment sets out the payment terms; it does not describe a new transfer of the rights.

  • Initial payment: Apimeds must issue FreeT 350,000 shares of Apimeds common stock no later than December 1, 2026.
  • Independent valuation: Within 60 days of the November 12 amendment, the two companies must jointly appoint an independent specialist valuer to assess the fair value of the transferred rights.
  • Potential additional payment: If the valuation is higher than the value of the initial share payment, Apimeds must pay FreeT the difference within 30 days after the valuation is completed. Apimeds can choose to pay that amount in cash, shares, or a combination.
  • Scope of the deal: The rights were transferred under an agreement signed August 19. The amendment clarifies how FreeT will be compensated; it does not specify the rights’ valuation or the amount of any additional payment.

The 350,000-share issuance will add shares to Apimeds’ stock base. The final economic cost of the rights remains undetermined until the independent valuation is completed; any additional compensation could be paid in cash, stock, or both.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.